Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.

Date publication

décembre 2020

Journal

The Lancet. Haematology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DORVAUX Véronique

Tous les auteurs :
Roussel M, Moreau P, Hebraud B, Laribi K, Jaccard A, Dib M, Slama B, Dorvaux V, Royer B, Frenzel L, Zweegman S, Klein SK, Broijl A, Jie KS, Wang J, Vanquickelberghe V, de Boer C, Kampfenkel T, Gries KS, Fastenau J, Sonneveld P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33242444

Résumé

In part 1 of the two-part CASSIOPEIA study, treatment before and after autologous haematopoietic stem-cell transplantation (HSCT) with daratumumab plus bortezomib, thalidomide, and dexamethasone (D-VTd) significantly improved rates of stringent complete response and progression-free survival versus bortezomib, thalidomide, and dexamethasone (VTd) in patients with newly diagnosed multiple myeloma.

Mots clés

Antibodies, Monoclonal, pharmacology, Antineoplastic Combined Chemotherapy Protocols, Bortezomib, pharmacology, Dexamethasone, pharmacology, Female, Humans, Male, Multiple Myeloma, drug therapy, Quality of Life, psychology, Thalidomide, pharmacology

Référence

Lancet Haematol. 2020 12;7(12):e874-e883